Project Details
Projekt Print View

Pathophysiological studies in neonatal tracheal aspirate derived mesenchymal stromal cells and animal models to determine the role of Pbx1 and other candidate genes in congenital diaphragmatic hernia.

Subject Area Pediatric and Adolescent Medicine
Term from 2021 to 2022
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 461188606
 
Final Report Year 2023

Final Report Abstract

Congenital diaphragmatic hernia (CDH) affects 1 in 2500 newborns. lt is characterized by underdeveloped lungs and a congenital defect in the diaphragm. Despite advances in intensive medical and surgical therapy, up to 30% of patients still succumb to lung malformations, and survivors often suffer from lifelong complications. Our limited understanding of the pathophysiology hinders the development of innovative therapeutic approaches. An established animal model, the Nitrofen rat model, is used for experimental investigation of CDH and has revealed changes in specific molecular markers in the hypoplastic CDH lungs. However, to date, these findings have only been partially applicable to the human situation. In this study, we cumulatively demonstrated that pro-inflammatory signaling pathways are particularly enriched in abnormal lung development in the animal model and in CDH in humans. Targeted blockade of these pathologically altered pathways led to the correction of impaired lung growth. To do this, we initially established a new method for isolating epithelial lung stem cells from routinely collected tracheal aspirates of newborns and investigated them in culture using functional and descriptive assays. In epithelial precursor cells from newborns with CDH, we identified transcriptional (bulk RNA sequencing) and epigenetic profiles {ATAC sequencing) indicating pro-inflammatory changes, including increased activity of the transcription factor NF-kB. Inhibition of NF-kB using glucocorticoids and specific NF-kB antagonists corrected the typical CDH phenotype in both human cell lines and the animal model. In a previous study using the established Nitrofen rat model for CDH, we identified a comparable pro-inflammatory program during later lung development in hypoplastic lungs through proteomic analyses (untargeted proteomics). The results from our in vitro studies in humans and in vivo studies in the animal model were validated through immunostaining in human fetal lung tissue from CDH patients and controls. In summary, we have shown in various translational models that a pro-inflammatory molecular program is active in hypoplastic CDH lungs, which could serve as a target for new therapeutic approaches to treat lung hypoplasia in CDH.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung